Alessandro Testori
A5021447572- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Nonmelanoma Skin Cancer Studies
- Cell Image Analysis Techniques
- Optical Coherence Tomography Applications
- Cancer Genomics and Diagnostics
- AI in cancer detection
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Cell Adhesion Molecules Research
- Sarcoma Diagnosis and Treatment
- Microbial Inactivation Methods
- Breast Cancer Treatment Studies
- Cutaneous lymphoproliferative disorders research
- Heat shock proteins research
- vaccines and immunoinformatics approaches
- Telomeres, Telomerase, and Senescence
- Skin Protection and Aging
- Toxin Mechanisms and Immunotoxins
- Peptidase Inhibition and Analysis
- Click Chemistry and Applications
- Colorectal Cancer Treatments and Studies
European Organisation for Research and Treatment of Cancer
2009-2024
Istituto Nazionale di Fisica Nucleare, Sezione di Milano
2023
Policlinico San Matteo Fondazione
2019-2021
Istituti di Ricovero e Cura a Carattere Scientifico
2013-2021
Boulder Community Hospital
2018-2020
European Institute of Oncology
2010-2019
GTx (United States)
2018
EMO GVM Centro Cuore Columbus
2018
Ceinge Biotecnologie Avanzate (Italy)
2016-2017
Ripamonti
1999-2016
Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates more than 50% in patients with metastatic melanoma V600E mutation.
Ipilimumab monotherapy (at a dose of 3 mg per kilogram body weight), as compared with glycoprotein 100, improved overall survival in phase study involving patients previously treated metastatic melanoma. We conducted ipilimumab (10 kilogram) plus dacarbazine untreated
On the basis of data from a phase 2 trial that compared checkpoint inhibitor ipilimumab at doses 0.3 mg, 3 and 10 mg per kilogram body weight in patients with advanced melanoma, this evaluated dose who had undergone complete resection stage III melanoma.After cutaneous we randomly assigned them to receive (475 patients) or placebo (476) every weeks for four doses, then months up years until disease recurrence an unacceptable level toxic effects occurred. Recurrence-free survival was primary...
Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., until death from melanoma) among patients node-positive intermediate-thickness melanomas (1.2 to 3.5 mm). The value of completion lymph-node dissection for sentinel-node metastases not clear.
It is widely held that cells with metastatic properties such as invasiveness and expression of matrix metalloproteinases arise through the stepwise accumulation genetic lesions arising from instability “clonal evolution.” By contrast, we show here in melanomas can be regulated epigenetically by microphthalmia-associated transcription factor, Mitf, via regulation DIAPH1 gene encoding diaphanous-related formin Dia1 promotes actin polymerization coordinates cytoskeleton microtubule networks at...
There is evidence from nonrandomized studies that a proportion of ipilimumab-treated patients with advanced melanoma experience long-term survival. To demonstrate survival benefit ipilimumab, we evaluated the 5-year rates treated in randomized, controlled phase III trial.A milestone analysis was conducted to capture rate treatment-naive who received ipilimumab trial. Patients were randomly assigned 1:1 receive at 10 mg/kg plus dacarbazine (n = 250) or placebo 252) weeks 1, 4, 7, and followed...
PURPOSE: To determine the immunogenicity and antitumor activity of a vaccine consisting autologous, tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96, Oncophage; Antigenics, Inc, Woburn, MA) in metastatic (American Joint Committee on Cancer stage IV) melanoma patients. PATIENTS AND METHODS: Sixty-four patients had surgical resection tissue required for production, 42 were able to receive vaccine, 39 assessable after one cycle vaccination (four weekly injections). In 21...
Purpose Adjuvant pegylated interferon alfa-2b (PEG-IFN-α-2b) was approved for treatment of resected stage III melanoma in 2011. Here, we present long-term follow-up results this pivotal trial. Patients and Methods In all, 1,256 patients with were randomly assigned to observation (n = 629) or PEG-IFN-α-2b 627) an intended duration 5 years. Stratification factors microscopic (N1) versus macroscopic (N2) nodal involvement, number positive nodes, ulceration tumor thickness, sex, center....
Elesclomol, an investigational first-in-class compound, induces oxidative stress, triggers mitochondrial-induced apoptosis in cancer cells, and shows synergy with taxanes tumor models. Following completion of a phase II trial elesclomol combination paclitaxel that met its primary end point progression-free survival (PFS), this randomized, double-blind, controlled III study was conducted to confirm the efficacy tolerability versus alone patients advanced melanoma.Patients stage IV...
BackgroundThe BRIM-3 trial showed improved progression-free survival (PFS) and overall (OS) for vemurafenib compared with dacarbazine in treatment-naive patients BRAFV600 mutation–positive metastatic melanoma. We present final OS data from BRIM-3.Patients methodsPatients were randomly assigned a 1 : ratio to receive (960 mg twice daily) or (1000 mg/m2 every 3 weeks). PFS co-primary end points. was assessed the intention-to-treat population, without censoring of who crossed over...
Active immunization against the tumor-specific MAGE-A3 antigen is followed by a few but impressive and durable clinical responses. This randomized phase II trial evaluated two different immunostimulants combined with protein to investigate whether more robust persistent immune response could be associated increased benefit.Patients MAGE-A3-positive stage III or IV M1a melanoma were randomly assigned receive either AS02B AS15 immunostimulant. Clinical end points toxicity rates of objective...
The sixth “Melanoma Bridge Meeting” took place in Naples, Italy, December 1st–4th, 2015. four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news immunotherapy; 4) tumor microenvironment biomarkers. Recent advances biology immunology has led to the development of new targeted immunotherapeutic agents that prolong progression-free survival (PFS) overall (OS) cancer patients. Immunotherapies particular have emerged as highly...